Itau Unibanco Holding S.A. acquired a new position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG – Free Report) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 5,106 shares of the medical equipment provider’s stock, valued at approximately $2,271,000.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Creekmur Asset Management LLC lifted its position in shares of Intuitive Surgical by 200.0% in the first quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 42 shares in the last quarter. Ridgewood Investments LLC acquired a new position in Intuitive Surgical in the 2nd quarter valued at $26,000. Able Wealth Management LLC purchased a new position in Intuitive Surgical in the 4th quarter valued at $28,000. Delos Wealth Advisors LLC lifted its holdings in Intuitive Surgical by 380.0% in the 1st quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 57 shares in the last quarter. Finally, LRI Investments LLC acquired a new stake in Intuitive Surgical during the 1st quarter worth $30,000. 83.64% of the stock is owned by hedge funds and other institutional investors.
Intuitive Surgical Stock Performance
Intuitive Surgical stock opened at $486.20 on Friday. The firm has a 50 day moving average price of $468.01 and a 200 day moving average price of $425.12. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $496.18. The company has a market capitalization of $172.46 billion, a PE ratio of 87.76, a price-to-earnings-growth ratio of 5.41 and a beta of 1.39.
Insider Transactions at Intuitive Surgical
In related news, Director Amal M. Johnson sold 2,943 shares of Intuitive Surgical stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $443.30, for a total value of $1,304,631.90. Following the completion of the transaction, the director now owns 12,275 shares in the company, valued at $5,441,507.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Intuitive Surgical news, Director Amy L. Ladd sold 450 shares of the stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $490.28, for a total value of $220,626.00. Following the sale, the director now owns 821 shares of the company’s stock, valued at approximately $402,519.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Amal M. Johnson sold 2,943 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $443.30, for a total transaction of $1,304,631.90. Following the sale, the director now owns 12,275 shares in the company, valued at $5,441,507.50. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 53,120 shares of company stock valued at $25,528,753. 0.90% of the stock is currently owned by corporate insiders.
Analysts Set New Price Targets
A number of equities research analysts have recently commented on the stock. Citigroup increased their target price on shares of Intuitive Surgical from $512.00 to $560.00 and gave the company a “buy” rating in a research report on Thursday, August 22nd. Barclays increased their price objective on shares of Intuitive Surgical from $430.00 to $490.00 and gave the company an “overweight” rating in a report on Thursday, July 18th. Piper Sandler raised their target price on shares of Intuitive Surgical from $490.00 to $495.00 and gave the stock an “overweight” rating in a research note on Friday, July 19th. BTIG Research upped their price target on Intuitive Surgical from $469.00 to $494.00 and gave the company a “buy” rating in a research report on Wednesday, August 28th. Finally, The Goldman Sachs Group started coverage on Intuitive Surgical in a report on Thursday, May 30th. They issued a “buy” rating and a $500.00 price target for the company. Six equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat, Intuitive Surgical has an average rating of “Moderate Buy” and a consensus target price of $446.45.
Read Our Latest Stock Report on Intuitive Surgical
Intuitive Surgical Company Profile
Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.
See Also
- Five stocks we like better than Intuitive Surgical
- How to Start Investing in Real Estate
- 3 Stocks That Could Rise on European Bank Interest Rate Cuts
- How to Invest in the FAANG Stocks
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- Golden Cross Stocks: Pattern, Examples and Charts
- MarketBeat Week in Review – 9/16 – 9/20
Receive News & Ratings for Intuitive Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intuitive Surgical and related companies with MarketBeat.com's FREE daily email newsletter.